270 related articles for article (PubMed ID: 17845846)
1. Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).
Booth CM; Calvert AH; Giaccone G; Lobbezoo MW; Eisenhauer EA; Seymour LK
Eur J Cancer; 2008 Jan; 44(1):25-9. PubMed ID: 17845846
[TBL] [Abstract][Full Text] [Related]
2. Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT).
Booth CM; Calvert AH; Giaccone G; Lobbezoo MW; Seymour LK; Eisenhauer EA
Eur J Cancer; 2008 Jan; 44(1):19-24. PubMed ID: 17890079
[TBL] [Abstract][Full Text] [Related]
3. Design and conduct of early clinical studies of two or more targeted anticancer therapies: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.
Seymour LK; Calvert AH; Lobbezoo MW; Eisenhauer EA; Giaccone G;
Eur J Cancer; 2013 May; 49(8):1808-14. PubMed ID: 23428669
[TBL] [Abstract][Full Text] [Related]
4. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
LoRusso PM; Boerner SA; Seymour L
Clin Cancer Res; 2010 Mar; 16(6):1710-8. PubMed ID: 20215546
[TBL] [Abstract][Full Text] [Related]
5. Targeted agents: how to select the winners in preclinical and early clinical studies?
Goodwin R; Giaccone G; Calvert H; Lobbezoo M; Eisenhauer EA
Eur J Cancer; 2012 Jan; 48(2):170-8. PubMed ID: 22093946
[TBL] [Abstract][Full Text] [Related]
6. Improving the design of phase II trials of cytostatic anticancer agents.
Stone A; Wheeler C; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
[TBL] [Abstract][Full Text] [Related]
7. Novel designs and end points for phase II clinical trials.
Adjei AA; Christian M; Ivy P
Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
[TBL] [Abstract][Full Text] [Related]
8. Translation of innovative designs into phase I trials.
Rogatko A; Schoeneck D; Jonas W; Tighiouart M; Khuri FR; Porter A
J Clin Oncol; 2007 Nov; 25(31):4982-6. PubMed ID: 17971597
[TBL] [Abstract][Full Text] [Related]
9. [Methodological approaches of clinical studies with targeted therapies].
Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
[TBL] [Abstract][Full Text] [Related]
10. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
Sharma MR; Maitland ML; Ratain MJ
Cancer J; 2009; 15(5):426-30. PubMed ID: 19826363
[TBL] [Abstract][Full Text] [Related]
11. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
[TBL] [Abstract][Full Text] [Related]
12. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
El-Maraghi RH; Eisenhauer EA
J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
[TBL] [Abstract][Full Text] [Related]
13. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
Taylor JM; Braun TM; Li Z
Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
[TBL] [Abstract][Full Text] [Related]
14. Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT).
Smoragiewicz M; Adjei AA; Calvo E; Tabernero J; Marabelle A; Massard C; Tang J; de Vries EGE; Douillard JY; Seymour L;
Clin Cancer Res; 2020 Jun; 26(11):2461-2465. PubMed ID: 32086344
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II designs in cancer clinical trials: current status and future directions.
Lee JJ; Feng L
J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical trials in oncology: are we hitting the target?
Ang MK; Tan SB; Lim WT
Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
[TBL] [Abstract][Full Text] [Related]
17. Trial design for evaluation of novel targeted therapies.
Farley J; Rose PG
Gynecol Oncol; 2010 Feb; 116(2):173-6. PubMed ID: 19853899
[TBL] [Abstract][Full Text] [Related]
18. Bivariate sequential designs for phase II trials.
Conaway MR; Petroni GR
Biometrics; 1995 Jun; 51(2):656-64. PubMed ID: 7662852
[TBL] [Abstract][Full Text] [Related]
19. Optimizing randomized phase II trials assessing tumor progression.
Stone A; Wheeler C; Carroll K; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
[TBL] [Abstract][Full Text] [Related]
20. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
Araujo D; Greystoke A; Bates S; Bayle A; Calvo E; Castelo-Branco L; de Bono J; Drilon A; Garralda E; Ivy P; Kholmanskikh O; Melero I; Pentheroudakis G; Petrie J; Plummer R; Ponce S; Postel-Vinay S; Siu L; Spreafico A; Stathis A; Steeghs N; Yap C; Yap TA; Ratain M; Seymour L
Ann Oncol; 2023 Jan; 34(1):48-60. PubMed ID: 36182023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]